Asciminib
Who holds supplier records for Asciminib? 1 organisation holds a current record for Asciminib: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (1).
Most records are filed under another form of this substance: Asciminib Hydrochloride (3 current sources). A DMF or CEP is listed under the form it names.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Asciminib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/asciminib
Reading the evidence
- One current record
One organisation holds a current DMF or CEP. A record shows a regulatory filing, not current commercial availability or a qualified source for your product.
- No company-level GMP certificate matched
No current EU or UK GMP certificate was matched to these organisations. That is not a negative finding; ask each candidate for its certificate and latest inspection outcome.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Asciminib expires 17 May 2040. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (1)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Asciminib. Country is the organisation's recorded country, not necessarily the manufacturing site.
- BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITEDIndiaActive DMF 41393 · latest filing Feb 2025
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (3 listed products contain Asciminib). The latest listed patent expires 17 May 2040. The latest listed exclusivity runs to 29 Oct 2031. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Asciminib is a small molecule ABL kinase inhibitor developed for the treatment of chronic myeloid leukemia (CML). It represents a novel therapeutic approach by specifically targeting the ABL myristoyl pocket.
Chemical identity
- IUPAC name
- N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
- Canonical SMILES
- C1CN(C[C@@H]1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4
- InChIKey
- VOVZXURTCKPRDQ-CQSZACIVSA-N
- Synonyms
- Scemblix API, abl-001, abl001, abl001-nx, nvp-abl001
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Asciminib?
1 organisation holds an active US FDA Type II Drug Master File or a CEP for Asciminib: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Asciminib Drug Master Files are active?
BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 41393). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Asciminib?
Yes. The latest patent listed for an approved US product containing Asciminib expires 17 May 2040, across 3 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Asciminib supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Asciminib?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.